Prediction Case File
YouTubeTracking Live

Friends! In this video, I'm going to do a service now stock analysis & discuss the risks and upside potential of NOW stock

1 extracted signal · 0 resolved · 1 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
23 Apr 2026, 21:08 UTC
Recorded by Tahlil Plus
18 May 2026, 20:24 UTC
Video preview for Friends! In this video, I'm going to do a service now stock analysis & discuss the risks and upside potential of NOW stock
Source overview

AI-generated source summary

ServiceNow (NOW) has experienced a significant stock price decline, currently trading around $85.43, down 17% year-to-date. Despite missing earnings per share expectations (0.97 vs 0.96), the company beat revenue expectations and showed strong renewal rates around 97-98%. The stock is currently trading at a forward P/E ratio of 24, which is considered a multiple, particularly given the slowdown in EPS growth to around 15-20% annually in the coming years. The company's management, led by a charismatic CEO, is actively engaged in share buybacks and appears to believe the stock is undervalued. However, the market appears to be discounting the stock due to factors such as geopolitical concerns and possibly the high valuation multiple for its current growth trajectory. The valuation model suggests a target price of $192.51 within five years, implying a significant upside of 126% or an annualized return of approximately 18.24%, assuming the P/E ratio remains at 24.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Tracking Live
Signals
1
Extracted from this source
Open
1
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. Live evaluation in progress

    1 signal remains active.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.6
Tracked signals
323
Historical success
34.4%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail